Several studies have identified CD133 as a prominent CSCs marker associated with cancer progression and tumorigenesis in various tumors, including gliomas, colorectal cancer, pancreatic cancer, ovarian cancer, prostate carcinoma, and hepatocellular carcinoma [18,19]. Here, PROM1 is linked to glioma.